
## **LIV** Oncology Screening and Surveillance and Management Pathways

## **I.IV.**I Guideline Screening Model



No clinical
action required.
Patient has
screening tool
and is aware of
self-detection
awareness
information, and
referral pathway
to local
lymphoedema
service.
Discharged
from active

surveillance.

\*Patients at high risk of cancer related lymphoedema should be on the screening and surveillance pathway and should be monitored at baseline (pre-op), surgical review (6-8 weeks post op), 9 months, and thereafter at 1, 1.5, 2, 2.5 and 3 years. Relative volume change, TDC or BIS should be undertaken at these points to assess for lymphoedema.

LBCQ -Lymphoedema Breast Cancer Questionnaire; LLGLQm - Lower Limb and Genital Lymphoedema Questionnaire - for men; LLGLQw - Lower Limb and Genital Lymphoedema Questionnaire - for woman

compression garment, skin care and activity advice.
-> Monitor and wean off compression No

Lymphoedema

unresolved or

>10% Vol

Refer to

Lymphoedema

Service for specialist

management

Yes

Nο

Continue

surveillance up

to 3 -years \*

Sub-clinical

oedema / vol

change or

self-reported

symptoms /clinical

examination

Yes

No